Brought to you by 
MediGene, investors spin out Immunocore
20 Nov 2008
Executive Summary
Four months after announcing it would strengthen its focus on cancer and immunology programs, MediGene AG has decided to spin off its other pipeline projects into a new company, Immunocore Ltd. A majority interest is being sold to three private investors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Divestiture/Spin-Out
- Intra-Biotech Deal
- Partial Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MediGene, investors spin out Immunocore
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice